Philippe Kehren

CEO

Alexandre Blum

First quarter 2024 results

CFO

Earnings call

May 7th, 2024

Forenote

This presentation may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this presentation is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&D projects and other unusual items. Consequently, actual results or future events may differ materially from those expressed or implied by such forward-looking statements.

Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

This document does not constitute an offer to sell, or the solicitation of an offer to subscribe for or buy, any securities.

2

Introduction

Philippe Kehren

3

Safety at the heart of our operations

RIIR (Reportable Injuries and Illness per 200,000 work hours)

0.27

0.27

0.27

(47)

(45)

4

3

3

2

4

4

3

Q1

Q2

Q3

Q4

Q1

Q2

Q3

Q4

Q1

2022

2023

2024

H-RIIR

RIIR

4

Q1 2024 results

Strong FCF supported by resilient EBITDA, cost and capex discipline

1.2bn

265m

123m

1.6bn

19.8%

NET SALES

Underlying EBITDA

FCF1

Underlying Net Debt

ROCE2

-12% organic

-14% organic

1.4x leverage2

last 12 months

22.1% EBITDA margin

5

1. To Solvay shareholders from continuing operations

2. From continuing operations

Microscopic view of

Alve-One®

Enabling safer and more sustainable foamed end-products for automotive, footwear, building and construction, consumer goods.

6

Key Q1 accomplishments

to drive us forward

  • Capacity expansion in France, Italy linked to SOLVAir® bicarbonate and in China for photovoltaic grade H2O2
  • New bio-based carbon neutral Augeo® for the Americas
  • New sustainable blowing agent Alve-One
  • First cost savings initiatives already bearing fruit
  • Inaugural €1.5bn bond placement , strengthening our balance sheet

Financials

Alexandre Blum

7

1 201m in Q1 2024

VS

1 355m in Q1 2023

34m from volumes

positive for the first time in 7 quarters

Negative pricing

mostly reflecting the lower energy and raw material costs

8

Q1 Sales bridge

1,355

1,363

34

-196

Scope

Forex

Volume

1,201

conversion

& mix

Price

-12%

-11%

Q1 2023

Q1 2023

Q1 2024

Sales

Sales

Sales

(constant scope

and currency)

Q1 EBITDA bridge

MARGIN

-4.8pp

MARGIN

26.9%

22.1%

365 -56

307

9

-79

Scope

Forex

Volume

20

8

265

conversion

& mix

Net

Fixed

Other

pricing

costs

-14%

-27%

Q1 2023

Q1 2023

Q1 2024

EBITDA

EBITDA

EBITDA

(constant scope

and currency)

265m in Q1 2024

VS

365m in Q1 2023

Volumes growth

for the first time in 7 quarters

Negative net pricing

mostly from soda ash other businesses very resilient

Lower fixed costs

cost discipline in challenging environment structural savings initiatives

9

Basic Chemicals results

Soda Ash & Deriv.

Peroxides

Net Sales

EBITDA

EBITDA Margin

Q1 2024 (€m)

% YoY

% YoY organic

493

-18%

-18%

222

+13%

-6%

715

-10%

-15%

202

-19%

-22%

28.2%

Q1 Highlights

  • Soda Ash & Derivatives : lower sales driven by prices. Flat soda ash volumes with seaborne market volume offsetting lower demand in container glass applications in Europe and North America. Bicarbonate volumes up in food and pharma markets.
  • Peroxides : consolidation of the Peroxidos do Brasil sales mechanically increased top line. Though organically, sales decreased from lower pricing (lower energy cost environment), offset by recovery in volumes in most end markets, especially in Europe.

10

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Solvay SA published this content on 07 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 May 2024 01:33:06 UTC.